pioneer semaglutide The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes Post hoc analysis of SUSTAIN

These symptoms may signal a serious interaction or GLP-1related side effect that requires professional evaluation rather than over-the-counter treatment

4.3 Diabetic cardiomyopathy Extensive evidence supports the broad-spectrum cardioprotective properties of GLPs, which effectively counteract diverse cardiac pathologiessuch as pathological myocardial hypertrophy, viral or autoimmune myocarditis, atherosclerotic plaque development, sepsis-associated myocardial depression, ischemia-reperfusion injury, and cardiotoxicity triggered by chemotherapeutic agents (Ubaidillah et al., 2016

Some pharmacies also offer 1 mg/mL, 2 mg/mL, or 10 mg/mL formulations

See more information, here